Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCY636 in Healthy Participants and Moderate to Severe Atopic Dermatitis
NCT07604324Phase 1Recruiting
- Sponsor
- Novartis
- Start
- Jun 2026
- Primary completion
- Jan 2028
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of DCY636 in atopic dermatitis (AD) (14 cohorts), sponsored by Novartis. Primary endpoint: Incidence of adverse events and serious adverse events. Started Jun 2026; status: recruiting.
02
Drugs
DCY636
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07604324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07604324.